Back to Search
Start Over
Time for micro-RNAs in steatotic liver disease: a case-control study.
- Source :
- Frontiers in Endocrinology; 2024, p1-9, 9p
- Publication Year :
- 2024
-
Abstract
- One of the challenges of modern-day living is to resist the temptation of overfeeding and sedentariness and maintain a healthy body and mind. On a favorable genetic and epigenetic background, a high-fat diet combined with lack of physical exercise constitutes the foundation for severe metabolic disturbances including steatotic liver disease. In our case-control study, we had the aim of establishing the role of selected micro-RNAs--miR-122, miR-192, miR-33a, and miR-33b--as superior biomarkers for the diagnosis and prognosis of steatotic liver in a 36-patient cohort compared to 12 healthy controls. Initial results confirmed the decline in miR-122 expression as fatty liver is progressing. However, combinations of DmiRs, such as DmiR33a_192, DmiR33a_122, and DmiR33b_122, correlate with ultrasound steatosis grade (R2 = 0.78) while others such as DmiR33b_122 provide a high specificity and sensitivity in fatty liver disease with an area under the curve (AUC) of 0.85. Compared to classical biomarkers, micro-RNAs can be used for both diagnostic and prognostic purposes as their diminished expression in severe cases of steatosis is associated with higher risk of emerging hepatocellular carcinoma. Manipulating micro-RNAs through agomirs or antagomirs can be the answer to the yet unsolved problem of efficient therapy in MAFLD. [ABSTRACT FROM AUTHOR]
- Subjects :
- FATTY liver
MICRORNA
LIVER diseases
METABOLIC disorders
HEPATOCELLULAR carcinoma
Subjects
Details
- Language :
- English
- ISSN :
- 16642392
- Database :
- Complementary Index
- Journal :
- Frontiers in Endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 178902016
- Full Text :
- https://doi.org/10.3389/fendo.2024.1349524